Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579092 · ClinicalTrials.gov registry record · Phase 2
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
NCT06579092 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 310 participants.
The verdict
NCT06579092, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
Study Summary
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity
Interventions
- DRUG Placebo
- DRUG AZD5004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579092
The ClinicalTrials.gov registry entry for NCT06579092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06579092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06579092 about?
NCT06579092 is a clinical study titled "Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity". A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with ob...
What is the current status of trial NCT06579092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2024-10-08. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT06579092?
The interventions under investigation include: Placebo (DRUG), AZD5004 (DRUG).
Who is sponsoring clinical trial NCT06579092?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.